nationwide A4 study on anti-amyloid treatment for Alzheimer’s. The landmark study launched in 2014 assessed whether the investigational drug, solanezumab, could slow memory loss caused by the amyloid protein.
ADVERTISEMENTThe study invited older individuals (ages 65-85) who have normal cognition and memory but who may be at risk for developing Alzheimer’s to participate.
Researchers then used an imaging test called a PET scan with over 4,400 participants to measure amyloid buildup in the brain.
Read more on powerofpositivity.com